Artelo Biosciences reports FY24 EPS $3.05 vs $3.14 last year

“Each of our programs is slated to reach important clinical milestones in 2025,” said Gregory Gorgas, President and CEO of Artelo Biosciences (ARTL). “Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein inhibitor, has progressed rapidly and is expected to conclude in the second quarter of this year. Designed to harness the power of lipid signaling with broad therapeutic potential, ART26.12 is the first selective FABP5 inhibitor from our proprietary FABP platform to enter human studies. Modulation of lipid-signaling remains Artelo’s key strategy to develop innovative medicines to treat significant unmet needs.”